Vikelis, Michail
Argyriou, Andreas A.
Dermitzakis, Emmanouil V.
Spingos, Konstantinos C.
Makris, Nikolaos
Kararizou, Evangelia
Funding for this research was provided by:
Allergan
Article History
Received: 31 July 2018
Accepted: 11 September 2018
First Online: 17 September 2018
Ethics approval and consent to participate
: The principal investigator’s Institutional Review Board granted approval for the current study (Mediterraneo Hospital, protocol no. 2719). Written informed consent for participation was obtained from each patient before entering the study.
: Not applicable.
: MV has received investigator fees and/or advisory board member and/or consultancy and/or travel grants from Amgen, Allergan, Brain Therapeutics, Novartis, Reckitt Beckinser. AA has received honoraria and travel grants from Allergan, Greece and Novartis. EVD has received honoraria and travel grants from Allergan, Greece and is an investigator in an Amgen-sponsored clinical trial on migraine prophylaxis. KS has received honoraria and travel grants from Allergan, Greece. NM has received honoraria from Novartis. EΚ has no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.